# Research Idea Ranking

**Generated:** 2026-02-19T10:12:31.249085
**Model:** openai/gpt-5.2 (reasoning: high)
**Tokens:** 6486

---

### Rankings

**#1: Click to Prescribe — Do Electronic Prescribing Mandates Reduce Opioid Overprescribing?**
- **Score: 69/100**
- **Strengths:** Clear staggered policy variation with a large number of treated states and a well-motivated placebo outcome (fentanyl deaths) that can detect confounding from broad opioid-era shocks. Monthly VSRR data allows relatively tight timing alignment around effective dates and dynamic/event-study diagnostics.
- **Concerns:** Biggest risk is **concurrent-policy confounding** (PDMP enhancements, prescribing limits, naloxone access laws, opioid settlement spending, COVID-era healthcare disruptions) that may move overdose deaths at the same time and correlate with adoption timing. Also, **outcome-policy linkage is indirect**: EPCS plausibly affects prescribing, but translating that into mortality—especially post-2016 when illicit fentanyl dominates—may be attenuated/noisy.
- **Novelty Assessment:** **Moderately high novelty.** Opioid-policy DiD is enormous, but **EPCS mandates specifically** are much less studied than PDMPs and pill-mill laws; the “format mandate” angle is plausibly under-covered in economics with modern staggered DiD.
- **DiD Assessment (CS / staggered DiD):**
  - **Pre-treatment periods:** **Strong** (for 2020–2022 cohorts you have ~2015–2019+ pre; early adopters are a separate issue—handle via cohort restrictions)
  - **Selection into treatment:** **Marginal** (states may adopt in response to opioid/prescribing conditions; you’ll need to show no differential pre-trends in T40.2 and perhaps in prescribing proxies)
  - **Comparison group:** **Marginal** (never-treated states may differ systematically in opioid markets; you’ll rely heavily on event studies and robustness to alternative controls/weighting)
  - **Treatment clusters:** **Strong** (34 states treated)
  - **Concurrent policies:** **Marginal** (opioid policy environment is crowded; placebo outcome helps but is not a full solution if policies differentially affect T40.2 vs T40.4)
  - **Outcome-Policy Alignment:** **Marginal** — EPCS affects **prescribing modality** → may reduce forged/duplicative scripts and improve monitoring, but mortality is a downstream outcome affected by many channels (illicit substitution, treatment access).
  - **Data-Outcome Timing:** **Strong** — VSRR is **monthly**; you can code treatment at the effective month and avoid “treated-but-not-exposed” mechanical attenuation (as long as effective dates are coded precisely).
  - **Outcome Dilution:** **Marginal** — within **T40.2** you’re closer to the affected margin, but many “prescription opioid” deaths involve diverted legacy supply and polysubstance; effect sizes may be small in the fentanyl era.
- **Recommendation:** **PURSUE (conditional on: (i) restricting main estimates to cohorts with clean pre-periods and reliable VSRR coverage; (ii) building a serious concurrent-policy set or sensitivity design; (iii) showing strong event-study diagnostics and exploiting the T40.4 placebo plus additional negative controls if possible).**


---

**#2: From Pump Room to Paycheck — Workplace Lactation Accommodation Laws and Maternal Employment**
- **Score: 64/100**
- **Strengths:** High policy relevance with a plausibly understudied state-policy margin, and the proposed outcome (employment for mothers of infants) is much closer to the policy’s intended beneficiaries than many “big average” outcomes. Long panel (pre-2022) gives ample pre-treatment time for event studies.
- **Concerns:** **Data feasibility/power** is a real issue: CPS state-year cells for mothers with children <1 can be thin, and effects may be heterogeneous by occupation/firm size (laws often apply only above size thresholds). Also, adoption may correlate with broader female-friendly labor policies (paid leave, childcare initiatives), creating confounding unless you explicitly address it.
- **Novelty Assessment:** **High novelty.** Paid family leave is heavily studied, but workplace lactation accommodation laws are much less developed in economics causal work; this looks meaningfully differentiated.
- **DiD Assessment (CS / staggered DiD):**
  - **Pre-treatment periods:** **Strong** (2002–2022 gives many pre years for most adopters)
  - **Selection into treatment:** **Marginal** (likely driven by politics/advocacy, but could also coincide with evolving female labor force priorities; you must test for pre-trends)
  - **Comparison group:** **Marginal** (never-treated states pre-2022 may be systematically different; consider reweighting / matched DiD / region-specific trends)
  - **Treatment clusters:** **Strong** (34+ states)
  - **Concurrent policies:** **Marginal** (PFL, minimum wage, EITC, childcare expansions, pregnancy accommodations—many correlate with the same political economy)
  - **Outcome-Policy Alignment:** **Strong** — policy reduces the cost of remaining at/returning to work while breastfeeding; maternal employment/hours among mothers of infants is directly relevant.
  - **Data-Outcome Timing:** **Marginal** — CPS is **monthly** (good), but the proposal currently emphasizes **state-year** outcomes; if laws take effect mid-year, year aggregation creates partial exposure. This is fixable by moving to month-level or dropping partial-exposure windows.
  - **Outcome Dilution:** **Marginal** — sample (mothers with <1) is close, but only a subset are (i) employed, (ii) breastfeeding/pumping, and (iii) covered by the law (firm-size/worker coverage restrictions).
- **Recommendation:** **CONSIDER (upgrade to PURSUE if: (i) you demonstrate adequate CPS/ACS sample sizes or use multi-year pooling; (ii) code coverage intensity—firm-size thresholds, paid-break requirements—and exploit that heterogeneity; (iii) implement month-level timing or “first full year exposed” definitions).**


---

**#3: Banning the “Cure” — Conversion Therapy Bans and Youth Suicide Mortality**
- **Score: 42/100**
- **Strengths:** Important policy question with genuine public interest, and using mortality avoids self-report bias. Long-run CDC WONDER data provides many pre-periods and broad state coverage.
- **Concerns:** **Outcome dilution is a dealbreaker for average state suicide mortality**: conversion therapy exposure is rare and concentrated in a small subgroup, so any realistic causal effect on population-level suicide mortality rates is likely extremely small and hard to detect. In addition, treated vs never-treated states differ sharply politically and socially, raising major parallel-trends concerns even with event studies.
- **Novelty Assessment:** **Moderately high novelty.** There is a broader literature on LGBTQ-related policies and youth outcomes, but conversion therapy bans specifically are less studied; novelty is not the main limitation here—identification/power is.
- **DiD Assessment (CS / staggered DiD):**
  - **Pre-treatment periods:** **Strong** (WONDER since 1999)
  - **Selection into treatment:** **Marginal** (policy adoption is political/ideological; may correlate with evolving mental-health environments and reporting/certification practices)
  - **Comparison group:** **Weak** — never-treated states are disproportionately different (region, religiosity, firearm prevalence, mental-health systems), making credible counterfactual trends hard.
  - **Treatment clusters:** **Strong** (25+ treated states)
  - **Concurrent policies:** **Marginal** (LGBTQ protections, school policies, mental-health initiatives may move together; hard to isolate)
  - **Outcome-Policy Alignment:** **Marginal** — suicide mortality is relevant, but far downstream from the policy lever (licensed-provider ban) and affected by many intervening systems.
  - **Data-Outcome Timing:** **Marginal** — WONDER is annual; if bans become effective mid-year, first “treated year” is partial exposure (you’d need careful exposure definitions).
  - **Outcome Dilution:** **Weak** — affected group is far below 10% of the 10–24 population, and suicide is a low base-rate outcome even within the subgroup.
- **Recommendation:** **SKIP (unless redesigned).** A more viable design would need outcomes much closer to the treated population (e.g., crisis-line calls, ED visits for self-harm among LGBTQ youth if measurable; or subgroup-specific survey outcomes with enough treated states), or a setting with sharper targeting and higher exposure prevalence.


---

### Summary

This is a solid batch on novelty, but only **Idea 1** looks immediately “go” conditional on serious work to rule out concurrent-policy confounding; its placebo structure and monthly timing are genuine strengths. **Idea 3** is promising and novel but needs tighter implementation on timing, coverage intensity, and sample size/power. **Idea 2** fails on **outcome dilution** and likely **comparison-group credibility**, so it should be skipped unless fundamentally reframed around outcomes and samples much closer to the treated population.